Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMID^ in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival .
http://www.pmpnews.com/news/celgene-reports-phase-iii-study-oral-revlimid%C3%AF%C2%BF%C2%BD-newly-diagnosed-multiple-myeloma-meets-primary
http://www.pmpnews.com/news/celgene-reports-phase-iii-study-oral-revlimid%C3%AF%C2%BF%C2%BD-newly-diagnosed-multiple-myeloma-meets-primary
No comments:
Post a Comment